Cellectar Biosciences, Inc. announced a partnership to advance the treatment of Waldenstrom's macroglobulinemia (WM) in the community setting with American Oncology Network (AON) and Meaningful Insights-BioTech Analytics (MiBA). Positive topline data from the pivotal Clover WaM study for iopofosine I 131 was reported on January 8, achieving the primary endpoint with a 61% major response rate (MRR) and exceeding the protocol statistical hurdle of 20%. This was the largest study to date in relapsed or refractory WM patients post-BTKi therapy and represents the most refractory population ever tested in clinical studies based upon a review of published literature.

Iopofosine I 131 was well tolerated and its toxicity profile was consistent with the Company's previously reported safety data.